Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

RedHill Biopharma Announces Approval for Talicia®

Tuesday, September 19, 2023

RedHill Biopharma has received approval from the U.S. Food and Drug Administration (FDA) for a change in the dosing regimen of its drug, Talicia, used for the eradication of H. pylori infection. 

Talicia is a unique oral capsule that combines two antibiotics, amoxicillin and rifabutin, along with a proton pump inhibitor (PPI), omeprazole. It is the only low-dose rifabutin-based therapy approved for H. pylori treatment, offering a solution for cases where H. pylori has developed resistance to other antibiotics. The formulation and components of Talicia are optimised to ensure effective eradication of H. pylori.

H. pylori treatment can be complex for patients, often requiring multiple pills to be taken throughout the day. Simplified regimens like the new TID dosing of Talicia can greatly improve patient adherence, making it an attractive option for healthcare providers when choosing an H. pylori eradication therapy.

The flexibility in dosing, coupled with Talicia's proven efficacy, tolerability, and resistance profile, along with its status as the only all-in-one formulation available, positions it as a strong choice for first-line therapy in the empiric treatment of H. pylori infection. 

Talicia offers potential advantages over clarithromycin-based regimens for most patients, making it a promising option in the fight against H. pylori infection.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024